Felicity Hartnell, Ilaria Esposito, Leo Swadling, Anthony Brown, Chansavath Phetsouphanh, Catherine Lara, Chiara Gentile, Bethany Turner, Lucy Dorrell, Stefania Capone, Antonella Folgori, Eleanor Barnes, Paul Klenerman – 3 February 2020
Jianghua Zhou, Feng Zhou, Wenxin Wang, Xiao‐Jing Zhang, Yan‐Xiao Ji, Peng Zhang, Zhi‐Gang She, Lihua Zhu, Jingjing Cai, Hongliang Li – 3 February 2020
3 February 2020
Nabil Noureddin, Jörn M. Schattenberg, Naim Alkhouri, Mazen Noureddin – 3 February 2020
Gastón J. Piñeiro, Jordi Rovira, Enrique Montagud‐Marrahí, Jose V. Torregrosa, José Ríos, David Cucchiari, Jessica Ugalde‐Altamirano, Pedro Ventura‐Aguiar, Rosana Gelpi, Eduard Palou, Jordi Colmenero, Miquel Navasa, Fritz Diekmann, Nuria Esforzado – 3 February 2020 – Recipients of simultaneous liver‐kidney transplantations (SLKTs) have a lower risk of rejection compared with recipients of kidney transplants alone. However, there is disagreement about the impact of pretransplant anti–human leukocyte antigen sensitization on patient and kidney graft survival in the long term.
Alick Feng, Maen Masadeh, Arvind R. Murali – 31 January 2020
Alick Feng, Maen Masadeh, Arvind R. Murali – 31 January 2020
Shuang Wang, Scott L. Friedman – 31 January 2020
Racha T. Khalaf, Ronald J. Sokol – 31 January 2020 – Development of intestinal failure–associated liver disease (IFALD) is a common complication of long‐term parenteral nutrition (PN) in children and adults. The molecular and cellular mechanisms and the phases of IFALD are now being delineated. Components of PN lipid emulsions, including plant sterols, interact with hepatic innate immune activation promoted by products of gut bacterial overgrowth/dysbiosis and altered intestinal barrier function (gut‐liver axis) and by episodes of sepsis to cause cholestasis and IFALD.
Racha T. Khalaf, Ronald J. Sokol – 31 January 2020 – Development of intestinal failure–associated liver disease (IFALD) is a common complication of long‐term parenteral nutrition (PN) in children and adults. The molecular and cellular mechanisms and the phases of IFALD are now being delineated. Components of PN lipid emulsions, including plant sterols, interact with hepatic innate immune activation promoted by products of gut bacterial overgrowth/dysbiosis and altered intestinal barrier function (gut‐liver axis) and by episodes of sepsis to cause cholestasis and IFALD.